These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1624747)
1. The efficacy and safety of tissue plasminogen activator in acute ischemic strokes. Hoang KD; Rosen P J Emerg Med; 1992; 10(3):345-52. PubMed ID: 1624747 [TBL] [Abstract][Full Text] [Related]
2. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216 [TBL] [Abstract][Full Text] [Related]
3. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348 [TBL] [Abstract][Full Text] [Related]
4. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. GUSTO investigators N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123 [TBL] [Abstract][Full Text] [Related]
5. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
6. [Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction]. Shul'man VA; Radionov VV; Golovenkin SE; Pediashov VE; Linev KA; Titarenko OM; Simulin VN; Pasal'skiĭ VL; Peterson LS; Necheporenko GI; Kononova LI; Peterson EV Kardiologiia; 2004; 44(5):40-2. PubMed ID: 15159721 [TBL] [Abstract][Full Text] [Related]
8. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Phillips DA; Fisher M; Smith TW; Davis MA Ann Neurol; 1988 Apr; 23(4):391-4. PubMed ID: 3132892 [TBL] [Abstract][Full Text] [Related]
9. A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits. Hamilton MG; Lee JS; Cummings PJ; Zabramski JM Stroke; 1994 Mar; 25(3):651-5; discussion 656. PubMed ID: 8128521 [TBL] [Abstract][Full Text] [Related]
10. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Lyden PD; Madden KP; Clark WM; Sasse KC; Zivin JA Stroke; 1990 Nov; 21(11):1589-93. PubMed ID: 2122552 [TBL] [Abstract][Full Text] [Related]
11. [Thrombolytic therapy in ischemic infarct]. Willig V; Steiner T; Hacke W Wien Klin Wochenschr; 1997 Oct; 109(20):795-803. PubMed ID: 9454430 [TBL] [Abstract][Full Text] [Related]
12. Intravenous thrombolytic therapy in myocardial infarction: an analytical review. Shammas NW; Zeitler R; Fitzpatrick P Clin Cardiol; 1993 Apr; 16(4):283-92. PubMed ID: 8458108 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545 [TBL] [Abstract][Full Text] [Related]
17. Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator. Kimball BP; Bui S; Ling A; Dafopoulos N Am Heart J; 1992 Jan; 123(1):7-14. PubMed ID: 1729852 [TBL] [Abstract][Full Text] [Related]
18. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. Naylor CD; Armstrong PW CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946 [TBL] [Abstract][Full Text] [Related]
19. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
20. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. GUSTO Angiographic Investigators N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]